H
Hangzhou Chance Pharmaceuticals
A clinical-stage biotechnology company focusing on discovering
About Hangzhou Chance Pharmaceuticals
Hangzhou Chance Pharmaceuticals is a clinical-stage biotechnology firm established in 2015, specializing in the development and commercialization of inhalation therapies. The company was co-founded by Donghao Chen, who serves as CEO, along with Lan Chen, Peng Huang, and Guobao Zhao. Dr. Donghao Chen's background is deeply rooted in inhalation technology; he conducted post-doctoral training at M.I.T. in the lab that invented the ARCUS inhalation technology and later worked at Advanced Inhalation Research (AIR) and Alkermes as the CMC lead for an inhaled insulin therapy. This specialized experience provides a strong scientific foundation for the company's focus.
The company's business model centers on developing a pipeline of therapies for debilitating conditions such as chronic obstructive pulmonary disease (COPD), asthma, and central nervous system disorders. Revenue generation is anticipated through strategic partnerships, distribution agreements, and the eventual commercialization of its drug candidates. A key agreement was established with Acorda Therapeutics in May 2023 to distribute and supply INBRIJA®, a treatment for OFF episodes in Parkinson's disease patients, in Greater China. Under this agreement, Chance Pharmaceuticals will pay Acorda an upfront fee, along with milestone payments and a fixed fee per unit supplied.
Chance Pharmaceuticals leverages two core technology platforms for creating dry powder inhalation (DPI) therapies: a traditional milling and mixing platform and a proprietary spray-drying platform. The spray-drying technology is particularly notable as it allows for the formulation of biological macromolecules and low-activity drugs into highly efficient inhalation powders for deep lung or systemic delivery. The company's pipeline includes candidates like CXG87, an enhanced formulation of budesonide/formoterol inhalation powder currently advancing to Phase III clinical trials, and CXF11, a tiotropium bromide inhalation drug for preventing bronchospasm in COPD patients. To support its development and commercialization goals, the company is building manufacturing facilities compliant with FDA and EMA quality standards.
The company has successfully secured significant funding to advance its pipeline. It raised $30 million in a Series C round in October 2021, followed by a Series C+ round in January 2022. Most recently, in March 2025, Chance Pharma completed another funding round with participation from investors Heda Health Fund and Qihang Venture Capital to accelerate its Phase III trials and develop new formulations.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Mar 2025 | $0 | — | Undisclosed | ↗ |
| SERIES COther financing | Oct 2021 | $30M | $120M | Shenzhen Guozhong Venture Capital Management · CMS · HEDA Ventures · Lapam Capital | — |
Growth signals
Latest recorded traffic for Hangzhou Chance Pharmaceuticals is 290 monthly website visits, down 79.3% over the last three months. Hangzhou Chance Pharmaceuticals's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Hangzhou Chance Pharmaceuticals in the Hangzhou ecosystem
The Hangzhou Chance Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Delian Capital
Series A3 investors entered at this stage
Shenzhen Guozhong Venture Capital Management- KCKaitai Capital
- YPYipinhong Pharmaceutical
Series B and later3 investors entered at this stage
Lapam Capital- CMCMS
- HVHEDA Ventures
Other known investors1 additional known investor
Massachusetts Institute of Technology
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Hangzhou Chance Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Hangzhou Chance Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









